New study looks at FDA's use of so­cial me­dia to com­mu­ni­cate on drug safe­ty

A new study look­ing at the FDA use of so­cial me­dia to com­mu­ni­cate about drug safe­ty finds that the agency could im­prove its im­pact by de­vel­op­ing so­cial me­dia strate­gies and tak­ing a more ac­tive role on web plat­forms.

The study, con­duct­ed by re­searchers at Har­vard Med­ical School, North­east­ern Uni­ver­si­ty, Boston Chil­dren’s Hos­pi­tal and The Ohio State Uni­ver­si­ty, and fund­ed by FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search, looks specif­i­cal­ly at FDA’s use of so­cial me­dia fol­low­ing two drug safe­ty com­mu­ni­ca­tions (DSCs) for drugs con­tain­ing zolpi­dem, the ac­tive in­gre­di­ent in Am­bi­en.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.